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Objective: To investigate low-density lipoprotein receptor-related protein 1b (LRP1b) expression in
human tissues and to identify circulating ligands of LRP1b.
Methods and results: Using two independent RT-PCR assays, LRP1b mRNA was detected in human brain,
thyroid gland, skeletal muscle, and to a lesser amount in testis but absent in other tissues, includ-
ing heart, kidney, liver, lung, and placenta. Circulating ligands were puriﬁed from human plasma by
afﬁnity chromatography using FLAG-tagged recombinant LRP1b ectodomains and identiﬁed by mass
spectrometry. Using this technique, several potential ligands (ﬁbrinogen, clusterin, vitronectin, histidine
rich glycoprotein, serum amyloid P-component, and immunoglobulins) were identiﬁed. Direct binding
of LRP1b ectodomains to ﬁbrinogen was veriﬁed by co-immunoprecipitation. ApoE – carrying lipopro-ibrinogen
ipoproteins
teins were shown to bind to LRP1b ectodomains in a lipoprotein binding assay. Furthermore, binding as
well as internalization of very low density lipoproteins by cells expressing an LRP1b minireceptor was
demonstrated.
Discussion: LRP1b expression in humans appears to be conﬁned to few tissues, which could point out to
specialized functions of LRP1b in certain organs. Most of the newly identiﬁed LRP1b ligands are well-
known factors in blood coagulation and lipoprotein metabolism, suggesting a possible role of LRP1b in
atherosclerosis.
The LDL receptor family comprises seven known receptors in
ammals. All members share a common structure with a typical
rrangement of ligand binding repeats and epidermal growth fac-
or (EGF) receptor homology domains in their extracellular part.
hey fulﬁll a variety of different functions, ranging from the clas-
ical role in receptor-mediated endocytosis to integral roles in
ellular signaling pathways [1]. Low-density lipoprotein receptor-
elated protein 1b (LRP1b) is one of three very large receptors of
he family with a size of approximately 600kDa and shares the
reatest degree of homology (60% identical amino acid residuals)
ith LRP1. The unusually large LRP1b gene was discovered during
tudies of lung cancer cell lines, where alterations of the LRP1b
ene, as e.g., the deletion of individual exons, were frequently
bserved. Therefore, LRP1b was originally termed LRP – deleted in
umors (LRP–DIT) andwas postulated as a putative tumor suppres-
or [2]. The LRP1b mRNA encoded by 91 exons codes for a protein
∗ Corresponding author. Tel.: +43 51250481414; fax: +43 51250425770.
E-mail address: Peter.Marschang@i-med.ac.at (P. Marschang).
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of 4599 amino acids, which comprises four ligand binding domain
regions in the extracellular part. The expression of LRP1b in the
mouse has been described previously. Murine LRP1b expression is
highest in the brain, where the full-length receptor and an alterna-
tively spliced form lacking exon 90 are present. The alternatively
spliced form is also present in the adrenal gland and in the testis
[3]. The expression of LRP1b in human tissues is controversial. In
the ﬁrst description of the receptor, a broad expression of LRP1b
was reported (kidney, brain, lung, heart, liver) [2]. In a subsequent
paper, LRP1b transcripts were reported to be present in human
brain, thyroidglandandsalivaryglandonly [4]. Later, LRP1bexpres-
sion was reported in several human tissues (brain, adrenal gland,
salivary gland, testis, skeletal muscle, lung, kidney, small intes-
tine, prostate, thymus, heart, stomach) [5]. Independently, LRP1b
expression was described in normal human urothel, smooth mus-
cle cells of the arterial wall and recently in normal human gastric
Open access under CC BY-NC-ND license.tissue [6–8]. The homologous LRP1molecule is a broadly expressed
multiligand receptor withmore than 30 known ligands comprising
apo E carrying lipoproteins, proteases/antiprotease complexes, and
other molecules [9]. Some of these ligands, namely the receptor-
associated protein (RAP), urokinase plasminogen activator (uPA),
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PA receptor, plasminogen activator inhibitor type-1 (PAI-1), gp96,
nd pseudomonas exotoxin have also been shown to bind to LRP1b
4,10]. In addition, well known chaperones (RAP, gp96, sacsin,
edd7) and other proteins (synaptotagmin, GPR69a, laminin recep-
orprecursor, beta-amyloidprecursorprotein)havebeen identiﬁed
s LRP1b ligands [3,11]. Presently, the physiological role of LRP1b
nd possible functions of the receptor in diseases like cancer
nd atherosclerosis are largely unknown. In contrast to other LDL
eceptor family members [12], mice carrying a truncated form of
RP1b lacking the transmembrane region and therefore exclusively
xpressing a secreted extracellular domain appear phenotypically
ormal with normal plasma lipids [3]. Different from this ﬁnding,
ice with more proximal truncations of the receptor are embry-
nically lethal, suggesting important functions of the extracellular
art of LRP1b [13]. As stated above, LRP1b expression has been
escribed in smooth muscle cells of the arterial wall. In addition,
RP1b was shown to modulate the expression of the uPA receptor
nd of the platelet derived growth factor receptor  in endothe-
ial cells, thereby affecting the migration of smooth muscle cells
7,14]. These ﬁndings raise the possibility that LRP1b may play a
ole in the pathogenesis of atherosclerotic lesions. To further inves-
igate thephysiological functions of LRP1b,we set out to investigate
RP1b expression in human tissues and to search for circulating
xtracellular receptor ligands in human plasma.
. Methods
For detailed methods, please refer to the online-only
upplemental methods.
.1. Cell lines and cell culture
HEK293 cells (ATCC,Middlesex, UK), HEK293S cells (ATCC) CHO
ells (ldl-A7 subclone) [15], CHO ldl-A7 stably transfected with a
lasmid coding for a LRP1b region IV minireceptor [3] (TR 3517)
nd hepatoma HepG2 cells (ATCC) were cultured in DMEM. HEK
93S cells were stably transfected with plasmids coding for LRP1b
ctodomains II, III, and IV [3], grown in the same medium and
elected with G418.
.2. RNA isolation and cDNA preparation
Total RNA was isolated from cells using RNA STAT 60 from TEL-
EST Inc. (Friendswood, TX,USA). Twocommercial panelsofnormal
uman total RNA from 20 different tissues each were purchased
rom Ambion (Austin, TX, USA; panel A) and Clontech (Mountain
iew, CA, USA; panel B), respectively, and transcribed into cDNA.
.3. Conventional RT-PCR
Conventional RT-PCR was performed with speciﬁc primers
o amplify the cytoplasmic part of LRP1b (exons 89–90). Con-
rol reactions were carried out using glyceraldehyde-3-phosphate
ehydrogenase (G3PDH) speciﬁc primers. Primer sequences are
iven in the online-only supplemental methods.
.4. Real time RT-PCR
For real time PCR, primers corresponding to the extracellular
art of LRP1b close to the transmembrane region (exon–exon junc-
ion87/88)wereused. Results are shownas relative copynumber in
elation to a housekeeping gene (large ribosomal protein P0, RPLP0
16]). Primer sequences are given in the online-only supplemental
ethods.216 (2011) 342–347 343
1.5. Afﬁnity chromatography with immobilized LRP1b
ectodomains
Afﬁnity chromatography of potential ligands from human
plasma was performed using immobilized recombinant LRP1b
ectodomains as described previously [3]. Eluates were separated
on 4–15% SDS gels and individual bands were cut out and analyzed
by mass spectrometry.
1.6. Co-immunoprecipitation
Puriﬁed candidate ligands were incubated with recombinant
LRP1b ectodomains in the presence of the respective antibod-
ies at 4 ◦C over night. After centrifugation, the supernatants were
removed and the pellets were washed and separated on 4–15%
SDS gels. Western blotting was carried out using the M2 anti FLAG
antibody (Sigma–Aldrich) to detect bound LRP1b ectodomains.
1.7. Lipoprotein binding assay
Very low density lipoproteins (VLDL) and high density lipopro-
teins (HDL) were isolated by ultracentrifugation from human
plasma and labeled with biotin. Anti-FLAG agarose immobilized
LRP1b ectodomains were incubated over night with different
amounts of biotinylated lipoproteins. Binding was then quantiﬁed
after incubation with streptavidin peroxidase.
1.8. Immunocytochemistry
CHO ldl-A7 and TR 3517 cells were incubated with biotinylated
VLDL (250g/ml) at 37 ◦C or 4 ◦C for 4h. After washing, ﬁxed cells
were stained with peroxidase-labeled streptavidin.
1.9. Immunoﬂuorescence
CHO ldl-A7 and TR 3517 cells were ﬁxed with 4% paraformalde-
hyde and stainedwith a rabbit polyclonal antibody directed against
the carboxyl terminus of LRP1b described previously [3].
2. Results
2.1. LRP1b expression in human tissues
To detect LRP1b transcripts in human tissues, we applied both
conventional as well as real-time RT-PCR using different primer
pairs to amplify an intracellular (conventional RT-PCR) and an
extracellular (real-time RT-PCR) region of the LRP1b receptor,
respectively. As a positive control, we used CHO cells stably trans-
fected with a region IV LRP1b minireceptor (TR 3517 cells). HEK
293 cells expressing endogenous LRP1b were used as a weak posi-
tive control. As a negative control, the HepG2 cell line which does
not express LRP1b mRNA was used. Due to the design of the real
time primers around exon junction 87/88, false-positive signals by
contamination with genomic DNA can virtually be excluded. The
integrity of theRNAwasprovenby control ampliﬁcations ofG3PDH
and RPLP0, respectively. Two commercially available RNA panels
of normal human RNA from 20 different tissues were tested. As
depicted in Figs. 1 and 2, LRP1b mRNA is abundantly expressed in
human brain, thyroid gland, and skeletal muscle. Minor amounts
of LRP1b mRNA were detected in testis in one, but not in the other
RNA panel. In addition, LRP1b was found abundantly expressed in
other central nervous system tissues (cerebellum, fetal brain, spinal
chord, Table I of the online-only supplement). In all other tissues
tested (adipose tissue, bladder, colon, esophagus, fetal liver, heart,
kidney, liver, lung, placenta, prostate, salivary gland, small intes-
tine, spleen, stomach, thymus, trachea, and uterus) virtually no
344 J. Haas et al. / Atherosclerosis 216 (2011) 342–347
Fig. 1. Conventional RT-PCR: total RNA derived from different human tissues (RNA pane
using LRP1b speciﬁc primers to amplify a 400bp fragment of the cytoplasmic tail. Contro
agarose gels of a typical experiment repeated three times are shown.
Fig. 2. Real time RT-PCR: total RNA derived from two commercial RNA panels of
different human tissues was transcribed with reverse transcriptase and ampliﬁed
by real time PCR using LRP1b speciﬁc primers complementary to the exon junction
87/88of thehumanLRP1bcDNAsequence. LRP1bmRNAcontent is shownas relative
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Lopy number in relation to the housekeeping gene RPLP0± SEM. Data are mean
alues from two different RNA panels (panels A and B) and each column represents
ight ormore independentmeasurements. All other tissues tested (adipose, bladder,
olon, esophagus, fetal liver, heart, kidney, liver, lung, placenta, prostate, salivary
land, small intestine, spleen, stomach, thymus, trachea, and uterus) were negative.RP1b transcripts were detected. The results of the conventional
T-PCR were conﬁrmed by sequencing. It is noteworthy that the
lternatively spliced form lacking exon 90 described previously
n mouse tissues [3] was not found in any of the tissues exam-
ig. 3. Afﬁnity puriﬁcation using FLAG-tagged LRP1b ectodomains: (A) 3×FLAG-tagged LR
as passed through the columns and eluates were obtained with a 3× FLAG peptide. Po
tainedwith a colloidal blue staining kit. Unbound fractions (ﬂow through) and eluates fro
ingle bands were then cut out as indicated and proteins were analyzed by mass spectrom
RP1b ligand binding regions II, III and IV, respectively, are shown.l A) as indicated was transcribed with reverse transcriptase and ampliﬁed by PCR
l ampliﬁcations with G3PDH primers are shown in the lower panel. Representative
ined. This ﬁnding suggests that a predicted truncated alternative
LRP1b transcript (LRP1b 003) comprising the carboxyl terminal
part of LRP1b and lacking exon 90, that has been predicted in
genomic databases [17], is apparently not efﬁciently expressed (see
supplemental Figure I online).
2.2. Identiﬁcation of LRP1b ligands in human plasma
To screen for potential circulating LRP1b ligands in human
plasma,weusedafﬁnity chromatographyon immobilized recombi-
nant 3×FLAG-tagged LRP1b ectodomains containing ligandbinding
domain regions II, III or IV, respectively. After elutionwith a3×FLAG
peptide, potential LRP1b ligands were separated by SDS–PAGE and
subsequently identiﬁed by mass spectrometry (Fig. 3). Fibrino-
gen -chain and -chain were identiﬁed as ligands of ectodomain
IV. Several potential ligands were found that bind to ectodomain
II. These include ﬁbrinogen -chain, histidine rich glycoprotein
(HRG), clusterin, vitronectin, serum amyloid P-component (SAP),
and immunoglobulin chains (IGKV 1-5 and IGHA 1; see Table
II of the online-only supplement). Using this technique, no lig-
ands binding to ectodomain III were identiﬁed. To verify binding
to ectodomains, co-immunoprecipitation was carried out using
soluble recombinant ectodomains and puriﬁed potential ligands
(ﬁbrinogen and His-tagged clusterin). We found that ﬁbrinogen
binds strongly to ectodomain II and in a markedly lower intensity
P1b ectodomainswere immobilized on anti-FLAG agarose columns. Human plasma
tential ligands were separated on 4–15% SDS gels under reducing conditions and
ma column carrying 3×FLAG-labeled control protein (BAP)were loaded as controls.
etry. (B) The structures of the N-terminal 3×FLAG-tagged ectodomains containing
J. Haas et al. / Atherosclerosis 216 (2011) 342–347 345
Fig. 4. Co-immunoprecipitation: puriﬁed human ﬁbrinogen was incubated with
3×FLAG-tagged LRP1bectodomains in thepresenceof anti-ﬁbinogenantibodies and
GammaBind sepharose at 4 ◦C over night. Bound fractions were separated on 4–15%
SDS gels and Western blotting was carried out with the M2 anti-FLAG antibody
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Fig. 6. VLDL binding and internalization: CHO ldlA7 and TR 3517 cells were incu-
bated with biotinylated VLDL (250g/ml) for 4h at 4 ◦C (upper panels) or 37 ◦C
F
b
po detect LRP1b ectodomains. Control lanes 1–3 show the different electrophoretic
obility of ectodomains II, III and IV, whereas the co-immunoprecipitation of LRP1b
ctodomains is shown in lanes 4–6. Lane 7 is a control lane without ectodomains
howing two unspeciﬁc bands which are also present in the other IP lanes. A repre-
entative blot from three independent experiments is shown.
o ectodomains III and IV (Fig. 4). In contrast, we did not observe
irect binding of His-tagged clusterin to LRP1b ectodomains using
n analogous co-immunoprecipitation technique (data not shown).
ince clusterin is known to be present onHDL lipoprotein particles,
e set up a binding assay to assess lipoprotein binding to LRP1b
ctodomains. To ensure speciﬁc binding, control experimentswere
erformed using incubation with GST-RAP, known to inhibit bind-
ng of ligands to members of the LDL receptor family. As shown
n Fig. 5, puriﬁed HDL bound to ectodomain II while VLDL bound
o ectodomains II and IV. No signiﬁcant binding to ectodomain IV
ould be detected for HDL. In addition, none of the lipoproteins
ig. 5. Lipoprotein binding assay: M2 FLAG agarose-immobilized ectodomains II, III, and I
ound lipoproteins were detected by streptavidin peroxidase followed by a color reaction
resence of GST-RAP (- -- -). Data represent at least three independent experiments.(middle panels), respectively. Binding (at 4 ◦C) and internalization (at 37 ◦C) of VLDL
particleswas then shownby stainingwith steptavidine–peroxidase (200×). Efﬁcient
expression of the LRP1b minireceptor in TR 3517 cells is shown by staining with an
LRP1b speciﬁc antibody (bottom panels; 400×). Scale bars represent 80m.
showedbinding to ectodomain III. To extend theseﬁndingsweused
a cell line stably expressing an LRP1b minireceptor comprising the
ligand binding domain region IV (TR 3517). As shown in Fig. 6, TR
3517 cells efﬁciently bound VLDL particles at 4 ◦C and internalized
VLDL particles at 37 ◦C compared to the parent cell line CHO ldl-A7.3. Discussion
In this report, we describe a restricted expression of LRP1b, one
of the very large receptors of the LDL receptor family, in human
Vwere incubated over night at 4 ◦Cwith biotinylated VLDL and HDL. After washing,
. VLDL and HDL binding (––) are shown compared to control experiments in the
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issues. Of the different tissues examined, consistent LRP1b expres-
ion was observed only in human central nervous system, thyroid
land, and skeletal muscle. Minor amounts of LRP1b transcripts
ere found in one of two mRNA samples from testis. In all other
issues including liver, lung, kidney, intestine, spleen, and urinary
ladder, virtually no LRP1b transcripts could be detected. These
esults were obtained with two independent, highly sensitive RT-
CR methods. As stated above in the introduction, controversial
eports exist regarding the expression of LRP1b in human tissues
anging from restricted [4] to broad expression [2,5]. Previously,
e reported a similar restricted expression of LRP1b in the mouse
brain, adrenal gland, and testis). We cannot entirely explain the
onﬂicting data in the literature, but the disparities may be due to
ifferent techniques, different sources of RNA and possibly alter-
ative LRP1b transcripts that are listed in genetic databases [17].
ifferent from previous reports, we used two independent RT-PCR
ssays as well as two commercial mRNA panels from different
uppliers to analyze LRP1b expression. We cannot entirely rule
ut very low-level expression or LRP1b in specialized epithelia or
lood vessels, which may also have contributed to the equivocal
esults reported. However, our results of a restricted expression
f LRP1b in contrast to the broadly expressed homologous LRP1
eceptor, which is several fold higher expressed in virtually all tis-
ues examined, is also supported by expressed sequence tags in
he NCBI database (Table I of the online-only supplement). Since
RP1b was initially described as a tumor suppressor that is fre-
uently inactivated in different tumors, the lack of expression
n many tissues is surprising. To explain tumor-speciﬁc loss of
RP1b by mechanisms like homozygous deletions of exons, one
ould have to propose at least temporary expression of LRP1b
uring tumor development. Alternatively, LRP1b may be present
t certain phases in normal development and later be silenced by
pigenetic mechanisms, as has been described e.g., for esophageal
umors [18]. This hypothesis is supported by our ﬁnding of a low
ut reproducible expression of the receptor in human embryonic
idney cells (HEK-293) but apparent absence of LRP1b in adult
uman kidney tissue (Fig. 1). Interestingly, as already reported by
i et al. [5], we could not detect the alternatively spliced form of
he cytoplasmatic LRP1b tail (Fig. 1) and therefore no evidence
f the alternative shorter LRP1b-003 transcript predicted in the
nsembl database (Figure I of the online-only supplement). How-
ver, we cannot exclude the expression of this or other alternative
RP1b transcripts at low levels or in other tissues, as e.g., vascular
mooth muscle cells. Comparing LRP1b to the broadly and sev-
ral fold higher expressed, homologous LRP1 receptor, one could
peculate that LRP1b with its restricted expression may fulﬁll spe-
ialized functions in certain organs. Using afﬁnity chromatography
nd mass spectrometry, we were able to identify several poten-
ial LRP1b ligands binding to LRP1b ectodomains II and IV, but not
ctodomain III. Similar binding characteristics have been described
or LRP1with ligand binding domain regions II and IV being respon-
ible for the binding of nearly all known ligands [9]. Most of these
igands play important roles in blood coagulation, ﬁbrinolysis, cell
preading, and adhesion. The inﬂuence of LRP1b on these mech-
nisms may in part explain the proposed role of the receptor in
ell migration, as has been suggested by Tanaga et al. for vas-
ular smooth muscle cells [7]. For example, all three ﬁbrinogen
hains were found to bind to FLAG-tagged LRP1b ectodomains
I and IV. Fibrinogen binding to LRP1b ectodomains was demon-
trated independently by co-immunoprecipitation. Interestingly,
RP1 has been shown to bind ﬁbrinogen and to inhibit ﬁbrinogen
ccumulation on cell surfaces [19]. Besides itswell-known function
n coagulation, ﬁbrinogen plays important roles in cell spread-
ng, proliferation, and angiogenesis [20]. Another ligand binding
o ectodomain II is vitronectin, also known as complement S pro-
ein. Vitronectin is a plasma glycoprotein with diverse biologicals 216 (2011) 342–347
functions, including blood coagulation, ﬁbrinolysis, cell adhesion,
and spreading. Togetherwith clusterin, vitronectin is able to inhibit
cytolysis after binding to the terminal complement complex [21].
Vitronectin plays also a role in thrombin degradation by promoting
interaction of thrombin and PAI-1 followed by endocytosis of this
complex by LRP1 and megalin [22]. HRG is an abundant plasma
glycoprotein with many known ligands, including Zn2+, heparin,
plasminogen, and ﬁbrinogen. HRG is supposed to act as a extra-
cellular adaptor protein regulating physiological processes like
angiogenesis, cell adhesion andmigration, ﬁbrinolysis and coagula-
tion [23]. Another identiﬁedpotential LRP1b ligand is SAP, a protein
belonging to the family of pentraxins, which comprises mem-
bers as e.g., C-reactive protein. SAP plays an important role in the
humoral armof innate immunity,mediating e.g., pathogen recogni-
tion and apoptotic cell clearance [24].Wewere also able to identify
two immunoglobulin components as potential ligands for LRP1b:
IGHA1 protein, an immunoglobulin heavy chain of IGA and IGKV1-
5 protein, the variable region of immunoglobulin light chains.
Whether LRP1b may function as an immunoglobulin receptor has
to be investigated in further experiments. One ligand playing an
important role in lipoprotein metabolism and other physiological
pathways is clusterin, also known as apolipoprotein J. Clusterin is
known to circulate in plasma bound to HDL particles [25]. Together
with vitronectin, clusterin is a component of the terminal comple-
ment complex and mediates the folding of extracellular proteins
as a chaperone [26]. We were not able to verify clusterin binding
to LRP1b via immunoprecipitation, suggesting indirect binding of
clusterin to LRP1b, probably via binding of HDL particles or after
interaction with vitronectin. However, since binding of clusterin
to two other LDL receptor family members, namely megalin [27]
and apolipoprotein E receptor-2 [28], has been described, we can-
not exclude direct binding of clusterin to LRP1b, which might have
been inhibited by the His tag of the clusterin construct used in
our experiments. Members of the LDL receptor family participate
in the regulation of lipid metabolism, inﬂuencing atherosclero-
sis, neurodevelopment, regulation of nutrients and vitamins [29].
Most LDL receptor family members have been shown to bind
apoE – carrying lipoproteins, which is probably true for all these
structurally related molecules [30]. To formally prove lipoprotein
binding by LRP1b, we set up a binding assay using biotin-labeled
human lipoproteins which revealed binding of LRP1b ectodomains
to apoE containing lipoproteins (HDL and VLDL). With our cell cul-
ture experiments using LRP1b minireceptor expressing TR 3517
cells we could prove that LRP1b can indeed bind and internalize
lipoproteins like VLDL. However, given the restricted tissue distri-
bution and relatively low expression compared to the homologous
LRP1, it is not likely that LRP1b plays a major role in the clearing
of circulating lipoproteins from plasma. Alternatively, lipoproteins
and other ligands may induce signaling events mediated by the
large LRP1b cytoplasmic tail. Further studies of the expression of
LRP1b in normal arteries and atherosclerotic lesions as well as
the interactions between LRP1b and these ligands will be neces-
sary to gain more insight into the possible function of LRP1b in
atherosclerosis. Given the multifunctionality of the homologous
LRP1 receptor with more than 30 known ligands [9], it would not
be surprising to see LRP1b having multiple functions as well. It
has to be shown in which LRP1b expressing tissues and cells lig-
and binding is taking place and which mechanisms follow after
receptor–ligand interaction.Sources of funding
This work was supported by grant P 20825-B05 of the Austrian
Science Fund (FWF) to P.M.
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